IGC Pharma Inc (IGC)
| Market Cap | 32.53M |
| Revenue (ttm) | 1.35M |
| Net Income (ttm) | -13.00M |
| Shares Out | 75.64M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,918 |
| Open | 0.426 |
| Previous Close | 0.439 |
| Day's Range | 0.421 - 0.440 |
| 52-Week Range | 0.250 - 0.910 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 3.25 (+655.64%) |
| Earnings Date | Aug 8, 2024 |
About IGC
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from Alzheimer's under the Hyalolex brand name; CBD based tinctures, capsules, and topical analgesic cre... [Read more]
Financial Performance
In 2023, IGC Pharma's revenue was $1.35 million, an increase of 47.64% compared to the previous year's $911,000. Losses were -$13.00 million, 13.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for IGC stock is "Strong Buy" and the 12-month stock price forecast is $3.25.
News
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease.
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets.
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Publishes Study in European Society of Medicine.
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1.
IGC Pharma to Attend BIO International Convention 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Attend BIO International Convention 2024.
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two.
IGC Pharma Adds Advisor in Artificial Intelligence
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Adds Advisor in Artificial Intelligence.
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock.
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation.
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024.
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma (IGC)- Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline.
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Ascendiant Coverage.
IGC Pharma Reports Third Quarter Fiscal 2024 Results
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Third Quarter Fiscal 2024 Results.
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--TGR-63 Reduces Agitation in Alzheimer's Mouse Model.
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Breakthrough - Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's.
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial.
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's.
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University's Center for...
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives.
IGC Pharma Reports Second Quarter Fiscal 2024 Results
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Second Quarter Fiscal 2024 Results.
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy.
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical Trials
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate.
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico.
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer's Association International Conference.